Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Notable: Usability of the EXPLORER Exoskeleton · Neurodevelopmental Disorders in Natural Environments Primary completion pushed from Apr 1, 2025 to Aug 1, 2026 MarsiBionicsNot applicable NCT06765070
  2. Notable: Lubricin-inspired Osteoarthritis Treatment: a Unique Solution Primary completion pushed from Jun 2027 to Mar 2028 Pleryon Therapeutics (Hangzhou) LimitedNot applicable NCT07611708
  3. Notable: Juläine (TM) · Atrophic Facial Acne Scars Primary completion pushed from Dec 2026 to Jan 2028 Nordberg Medical ABNot applicable NCT07058883
  4. Notable: Acellular Dermal Matrix Investigation in Breast Reconstruction Primary completion pushed from Dec 2026 to Dec 2027 RTI SurgicalNot applicable NCT06456554
  5. Notable: Novel Joint Distraction Knee Orthosis for Treating Medial Knee Osteoarthritis Primary completion pushed from Jun 1, 2026 to Sep 1, 2027 Icarus Medical InnovationsNot applicable NCT07439315
  6. Notable: HEARTFELT Study Primary completion pushed from Jan 1, 2028 to Dec 31, 2028 Heartfelt TechnologiesNot applicable NCT06222099
  7. Notable: Juläine™ in Improving Gluteal Skin Laxity in Adults Primary completion pushed from Apr 2027 to Jan 2028 Nordberg Medical ABNot applicable NCT07332650
  8. Notable: AccuraSee™ IOPCL for Secondary Implantation in the Capsular Bag to Improve Near and/or Intermediate Vision Following Previous Cataract Surgery Primary and study completion pushed from Mar 2026 to Dec 2027 OnPoint Vision IncNot applicable NCT06625749
  9. Notable: PGx Medication Safety Reviews · IDD Primary completion pushed from Jul 31, 2027 to Jul 31, 2028 GalenusRx, Inc.Not specified NCT07092852
  10. Notable: Multicentric Pilot Study for the Application of an Endourethral Device · Stress Urinary Incontinence Primary and study completion pushed from Dec 31, 2026 to Jun 30, 2027 Relief srlNot applicable NCT07327528
  11. Notable: Imatinib to Increase RUNX1 Activity · Germline RUNX1 Deficiency Primary completion pushed from Oct 30, 2026 to Oct 30, 2027 National Cancer Institute (NCI)Phase 1 NCT06090669
  12. Notable: Reduced Port Laparoscopic Gastrectomy for Gastric Cancer Primary and study completion pushed from Mar 1, 2027 to Mar 1, 2029 Nanchong Central HospitalNot applicable NCT04295473
  13. Notable: TTF-NGR Randomized Study - STS Primary completion pushed from Aug 2026 to Dec 2030 Universität MünsterPhase 3 NCT05597917
  14. Notable: Treatment of Post-Stroke Central Pain Primary and study completion pushed from Aug 1, 2026 to Aug 1, 2029 Nanchong Central HospitalNot applicable NCT07593313
  15. Notable: Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy Primary completion pushed from Sep 1, 2026 to Dec 1, 2027 Jinling Hospital, ChinaPhase 2 NCT06255223
  16. Notable: Estrogen Supplementation and Bone Health · CF Primary completion pushed from Jan 2027 to Jan 2028 Johns Hopkins UniversityPhase 4 NCT05704036
  17. Notable: Fisetin to Reduce Senescence and Mobility Impairment in PAD Primary completion pushed from Nov 2026 to Jun 30, 2027 Northwestern UniversityPhase 2 NCT06399809
  18. Notable: 6 Hour Oxaliplatin Infusions · Gastrointestinal Cancers Primary completion pushed from Aug 5, 2026 to Aug 5, 2027 Emory UniversityPhase 2 NCT03800693
  19. Notable: Dexmedetomidine Versus Ketamine on Inflammatory Response and Hemodynamic in Patients Primary completion pushed from Jun 1, 2026 to Jan 1, 2027 New Valley UniversityPhase 1/2 NCT06490731
  20. Notable: COMS for Chronic Ulcers Treatment Primary completion pushed from Aug 31, 2026 to Aug 31, 2027 Sebastian ProbstPhase 4 NCT06528873
  21. Notable: Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM Primary completion pushed from Mar 15, 2025 to Nov 15, 2026 Institute of Hematology & Blood Diseases Hospital, ChinaPhase 2 NCT05914662
  22. Notable: NUC-7738 · Advanced Solid Tumours and Lymphoma Primary and study completion pushed from Aug 2026 to Jul 2027 NuCana plcPhase 1/2 NCT03829254
  23. Notable: Ethnic Differences in Mechanisms of Action of Dupilumab Primary completion pushed from Dec 2026 to Jul 2027 University of MichiganPhase 4 NCT05268107
  24. Notable: Hysterosalpingogram (HSG) Experience And Tubal Spasm (HEAT) Study Primary and study completion pushed from Dec 2026 to Oct 2027 University of OklahomaEarly Phase 1 NCT07226310
  25. Notable: Third-Party Natural Killer Cells and Mogamulizumab · Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma Primary completion pushed from Oct 30, 2026 to Jul 30, 2027 John ReneauPhase 1 NCT04848064